Sorafenib is an oral multikinase inhibitor manufactured by Bayer Schering, Germany, which can inhibit cell proliferation and angiogenesis of tumors. The study included 30 patients with metastatic thyroid cancer without iodine uptake who were treated orally for more than 16 weeks; 2. 95% of the patients had a significant and rapid reduction in thyroglobulin levels, with an average reduction of 70%; 3. 53% of the patients had stable disease for 14-89 weeks; 4. the average progression-free survival time was 79 weeks; 5. 23% of the patients had a partial outcome for 14-89 weeks, The disease has improved. Recently, the drug has been marketed in mainland China, and we have been the first to start clinical application in China, and good results have been seen.